In our observation, most GLP-1 suspensions were preceded by an earlier restriction. That restriction is often a chance to address the cited issue. When the issue stays unresolved, later enforcement often follows the same signals. Restrictions resolved promptly rarely progress to suspension.
Your GLP-1 account is throttled. Spend cap compressed, or specific campaign objectives blocked, or every new creative routing to manual review. The account still runs, but not at full capacity. This is the restriction stage, the last window before Meta escalates to suspension. In our observation, the window closes fast in GLP-1 because Drugs and Pharmaceuticals is what we refer to as a categorical-enforcement category.
Here is the pattern Meta is watching, and the three concepts that separate a reversal from an escalation.
In our observation, GLP-1 accounts rarely hit a restriction for one ad. Restrictions fire when a pattern builds up. The pattern spans multiple ads, the landing page, and the Business Manager. Meta reviews the account as a connected system at this stage.
Ads Manager shows the symptom: a reduced spend cap, a blocked objective, or elevated review. The Graph API shows the pattern. That means which scenario fired, and how often. ComplyAi refers to this API-level view as the Enforcement Signal Layer. It surfaces the warning signals that put the account into a restriction.
In our observation, Meta most commonly restricts GLP-1 advertisers under four recurring patterns. ComplyAi groups these into four categories. The first is brand-drug conflation. That means creative that names Ozempic, Wegovy, or Mounjaro directly. The second is compounded-versus-FDA framing. That means compounded semaglutide sold as equal to on-label brand-drug results. The third is treatment-claim language. That means phrases like treats obesity, cures diabetes, or medically supervised outcomes. The fourth is body-imagery reviews. That means before-after shots or weight-loss testimonials.
In our observation, accounts move from ad-level rejection into a restriction when any one scenario fires repeatedly. In our observation, restrictions involving multiple scenarios correlate with faster escalation (ComplyAi Intelligence Graph, Q2 2026).
In our observation, most GLP-1 suspensions passed through a restriction first. The restriction stage is the primary opportunity for corrective action before escalation.
GLP-1 restrictions resolve in one of two ways. Meta reverses the restriction in the first review window when the cited scenario is addressed. That takes consistent corrective evidence across the surfaces Meta reviews. Unresolved restrictions continue into more review cycles. Some escalate to full suspension.
Meta groups GLP-1 enforcement under Drugs and Pharmaceuticals. Every restriction cites a specific scenario. In our observation, brand-drug conflation (Ozempic, Wegovy, Mounjaro named in creative) is the most common. Appeals that miss the cited scenario typically take longer to resolve.
Meta reviews three surfaces on appeal: the ad copy, the landing page, and the Business Manager Page identity. In our observation, Meta clears reviews more consistently when all three have been corrected. Corrections limited to one surface tend to slow review. If the Business Manager carries other flagged accounts, those surfaces enter the review as well.
In our observation, Meta's review window is short in Drugs and Pharmaceuticals. It is measured in days, not weeks. Earlier appeals correlate with higher overturn rates. Well-anchored appeals clear 30 to 35 percent of the time on the first pass (ComplyAi Intelligence Graph, Q2 2026). As the window closes, recovery outcomes are less predictable. Escalation becomes more likely.
Below are three example categories. Each contrasts a pattern commonly flagged in review with one more often seen in successful reviews.
In our observation, restrictions are more likely to reverse when these category shifts address the triggering pattern.
The restriction stage is short in GLP-1. In our observation, five patterns are consistently associated with restrictions that later escalate to suspension.
Appeals submitted while the flagged pattern is still running rarely clear review.
Why: In our observation, Meta continues to evaluate a still-firing pattern as unresolved.
Meta associates business assets across accounts within the same Business Manager.
Why: ComplyAi refers to this pattern as Asset Risk Propagation. In our observation, a new account is evaluated alongside the existing Business Manager history. It often re-restricts in the same review cycle.
Compliance disclaimers do not clear a flagged treatment claim.
Why: In our observation, Meta evaluates the claim itself, not the surrounding disclaimer. Disclaimers work at the regulatory layer. They do not clear the enforcement layer.
Unsolicited FDA and regulatory documents do not address the classifier trigger.
Why: In our observation, these documents are not typically linked to faster review.
GLP-1 restrictions are reviewed within a relatively short window.
Why: In our observation, delayed responses more often lead to escalation (ComplyAi Intelligence Graph, Q2 2026).